Pages that link to "Item:Q1773294"
From MaRDI portal
The following pages link to The evaluation of surrogate endpoints. (Q1773294):
Displaying 50 items.
- An information-theoretic approach to surrogate-marker evaluation with failure time endpoints (Q746103) (← links)
- Causal measures of the treatment effect captured by candidate surrogate endpoints (Q887978) (← links)
- A family of generalized linear models for repeated measures with normal and conjugate random effects (Q906532) (← links)
- Choice of units of analysis and modeling strategies in multilevel hierarchical models (Q957034) (← links)
- Using earlier measures in a longitudinal sequence as a potential surrogate for a later one (Q962388) (← links)
- Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS (Q1020068) (← links)
- Center-within-trial versus trial-level evaluation of surrogate endpoints (Q1623614) (← links)
- Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials (Q1658329) (← links)
- Generating random correlation matrices with fixed values: an application to the evaluation of multivariate surrogate endpoints (Q2008126) (← links)
- An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework (Q2143008) (← links)
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
- Statistical models for exposure-biomarker relationships with measurement error and censoring (Q2259942) (← links)
- Randomized discontinuation trials with binary outcomes (Q2320887) (← links)
- Simplified modeling strategies for surrogate validation with multivariate failure-time data (Q2445595) (← links)
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials (Q2475730) (← links)
- The identification of direct and indirect effects in studies with an unmeasured intermediate variable (Q2791838) (← links)
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials (Q2792764) (← links)
- Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
- Comparing biomarkers as principal surrogate endpoints (Q2893405) (← links)
- Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling (Q2894010) (← links)
- Bayesian adaptive trial design for a newly validated surrogate endpoint (Q2894012) (← links)
- Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework (Q2912363) (← links)
- Marginal Correlation in Longitudinal Binary Data Based on Generalized Linear Mixed Models (Q3064091) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- The Evaluation of Multiple Surrogate Endpoints (Q3078684) (← links)
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling (Q3119801) (← links)
- Quantifying intraclass correlations for count and time-to-event data (Q3188700) (← links)
- A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint (Q3434121) (← links)
- Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints (Q3445296) (← links)
- Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach (Q3445321) (← links)
- On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints (Q3465713) (← links)
- Evaluating Candidate Principal Surrogate Endpoints (Q3549407) (← links)
- Improving Semiparametric Estimation by Using Surrogate Data (Q3631474) (← links)
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm (Q3637000) (← links)
- Related Causal Frameworks for Surrogate Outcomes (Q3637001) (← links)
- Information Recovery in a Study With Surrogate Endpoints (Q4468554) (← links)
- The validation of surrogate endpoints in meta-analyses of randomized experiments (Q4489920) (← links)
- True endpoint reduction by surrogate endpoints (Q4638854) (← links)
- Statistical Methods for Clinical Studies in the Presence of Surrogate End Points (Q4785433) (← links)
- Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements (Q5122424) (← links)
- A joint marginalized multilevel model for longitudinal outcomes (Q5127107) (← links)
- Test the reliability of doubly robust estimation with missing response data (Q5170196) (← links)
- Unbalanced cluster sizes and rates of convergence in mixed-effects models for clustered data (Q5222463) (← links)
- Criteria for Multiple Surrogates (Q5226638) (← links)
- Surrogate Marker Evaluation from an Information Theory Perspective (Q5427415) (← links)
- Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data (Q5450466) (← links)
- Rejoinder on: ``Surrogate measures and consistent surrogates'' (Q5891280) (← links)
- Evaluation of longitudinal surrogate markers (Q6050955) (← links)
- Evaluating multiple surrogate markers with censored data (Q6055488) (← links)
- Proportion of treatment effect mediated by surrogate endpoints (Q6067311) (← links)
